Genmab | GEN - Interest Expense On Debt


Genmab reported DKK10M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Amarin USD 3K 5K Dec/2024
Amgen USD 657M 4M Mar/2026
argenx SE USD 1000K 172K Mar/2026
AstraZeneca USD 484M 181M Dec/2025
Bayer EUR 675M 87M Dec/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Demant DKK 398M 37M Dec/2025
Exelixis USD 23.4M 3.9M Sep/2023
Fresenius Medical Care EUR 79M 6M Mar/2026
Genmab DKK 10M 27M Dec/2025
GlaxoSmithKline GBP 167M 21M Mar/2026
GN Store Nord DKK 296M 42M Dec/2025
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
Insmed USD 20.08M 517K Mar/2026
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Lonza CHF 84M 14M Jun/2025
Merck EUR 104M 17M Mar/2026
Novartis USD 343M 39M Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 178M 203M Mar/2026
UCB EUR 49M 29M Dec/2025